Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Best Stocks for 2022: After Two Quarters, Who Holds The Lead?

In This Article:

At the end of each year, InvestorPlace invites its analysts and writers to take a stab at picking one stock they think will do better than the rest during the next year. Nine analysts chose stocks this year, and our readers chose their favorite in an open poll.

Of course, it’s impossible to talk about how everyone’s choices are stacking up without first addressing the elephant in the room, which is that very few stocks are actually doing well this year. The fact that any of our analysts managed to pick a stock that’s gone up in price this year is commendable.

We’ve passed the halfway point of 2022, and multiple major indexes have slipped into bear market territory, with the S&P 500 now down 20% and the Nasdaq down 28%.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

There have been plenty of headwinds for the market, from Russia’s invasion of Ukraine to the Federal Reserve raising interest rates, and it has had cascading effects for everyone, not just those buying stocks. From gas prices to rent prices, it seems nothing is immune — except, perhaps, for the Costco (NASDAQ:COST) hot dog, thank goodness.

Let’s take a look at the 10 stocks and how they’re doing so far.

ABBV

Abbvie

$153.62

ARHS

Arhaus

$4.95

DRRSF

Arianne Phosphate

$0.32

BMY

Bristol-Myers Squibb

$75.65

EPR

EPR Properties

$49.21

KLIC

Kulicke and Soffa

$45.43

NVDA

Nvidia

$157.62

POSAF

POSaBit Systems

$0.51

ROKU

Roku

$85.77

SAH

Sonic Automotive

$36.58

Best Stocks for 2022: AbbVie (ABBV)

Abbvie logo outside of a building
Abbvie logo outside of a building

AbbVie (NYSE:ABBV), chosen by Bob Ciura, is our second best performer this year with a gain of 11%. It’s an impressive result in a year that has seen many powerhouse companies plummet, but what might be even more impressive is its dividend.

ABBV stock is a Dividend King, which means it has raised its dividend every year for the past 50 years. There aren’t many Dividend Kings out there — 44 right now — and it comes with the tacit assurance that the stock will continue to support investors with a dividend for years to come.

AbbVie has continued to grow its portfolio of drugs both through R&D investments and acquisitions of other companies. It will lose its patent protection for Humira soon, but that’s no reason to doubt its future potential.

Arhaus (ARHS)

a nicely decorated living room
a nicely decorated living room

Source: Africa Studio / Shutterstock.com

Arhaus (NASDAQ:ARHS), chosen by Luke Lango, is the worst performing stock of the bunch so far, having lost 65% of its price. As Luke explains, it all comes down to the big problems facing the economy as a whole. “Rising mortgage rates have caused the housing market to come to a screeching halt,” he explains, which means people aren’t exactly in the mood to buy new furniture.